Prevalence of COVID-19 Antibodies Among Operating Room and Critical Care Staff at a Tertiary Teaching Hospital: A Cross-sectional Study
Overview
Authors
Affiliations
Objectives: To identify the prevalence of COVID-19 antibodies among operating room and critical care staff.
Methods: In this cross-sectional study, we recruited 319 Healthcare workers employed in the operation theater and intensive care unit of King Abdulaziz University Hospital (KAUH), a tertiary teaching hospital in Jeddah, Saudi Arabia between August 9, 2020 and November 2, 2020. All participants completed a 20-item questionnaire on demographic data and COVID-19 risk factors and provided blood samples. Antibody testing was performed using an in-house enzyme immunoassay and microneutralization test.
Results: Of the 319 participants, 39 had detectable COVID-19 antibodies. Five of them had never experienced any symptoms suggestive of COVID-19, and only 19 were previously diagnosed with COVID-19. The odds of developing COVID-19 or having corresponding antibodies increased if participants experienced COVID-19 symptoms (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.2-7.5) or reported contact with an infected family member (OR, 5.3; 95% CI, 2.5-11.2). Disease acquisition was not associated with employment in the ICU and involvement in the intubation of or close contact with COVID-19 patients. Of the 19 previously diagnosed participants, 6 did not possess any detectable COVID-19 antibodies.
Conclusions: Healthcare workers may have undiagnosed COVID-19, and those previously infected may not have long-lasting immunity. Therefore, hospitals must continue to uphold strict infection control during the COVID-19 pandemic.
Detection of COVID-19 incidence among attendees of the 2022 Hajj season.
Alandijany T, Qashqari F, Alfelali M, Hariri S, Hassan A, Faizo A IJID Reg. 2024; 13:100439.
PMID: 39399129 PMC: 11470398. DOI: 10.1016/j.ijregi.2024.100439.
Gender and sex differences in occupation-specific infectious diseases: a systematic review.
Biswas A, Tiong M, Irvin E, Zhai G, Sinkins M, Johnston H Occup Environ Med. 2024; 81(8):425-432.
PMID: 39168602 PMC: 11420758. DOI: 10.1136/oemed-2024-109451.
Faizo A, Bawazir A, Almashjary M, Hassan A, Qashqari F, Barefah A Vaccines (Basel). 2023; 11(2).
PMID: 36851205 PMC: 9965425. DOI: 10.3390/vaccines11020327.
Prognosis of COVID-19 in the middle eastern population, knowns and unknowns.
Dandachi I, Aljabr W Front Microbiol. 2022; 13:974205.
PMID: 36118201 PMC: 9471247. DOI: 10.3389/fmicb.2022.974205.
Mushcab H, Al-Tawfiq J, Ghamdi M, Babgi A, Amir A, Sheikh S Infect Drug Resist. 2022; 15:4393-4406.
PMID: 35974896 PMC: 9375977. DOI: 10.2147/IDR.S369755.